

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 June 2022 (09.06.2022)



(10) International Publication Number
WO 2022/117799 A3

(51) International Patent Classification:

A61K 39/395 (2006.01) A61K 31/475 (2006.01)
C07K 16/28 (2006.01) A61K 31/573 (2006.01)
A61P 35/00 (2006.01) A61K 31/675 (2006.01)
A61P 35/02 (2006.01) A61K 31/704 (2006.01)
A61K 31/454 (2006.01)

[US/US]; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(72) Inventors: **FINGERLE-ROWSON, Günter**; Bozener Strasse 7, 82319 Starnberg (DE). **BRUGGER, Wolfram**; Buchhierlstraße 9, 81479 Munich (DE). **MANZKE, Oliver**; Incyte Biosciences International Sàrl, Rue Docteur-Yersin 10, 1110 Morges (CH). **SEGUY, Francis**; Incyte Biosciences International Sàrl, Rue Docteur-Yersin 10, 1110 Morges (CH).

(21) International Application Number:

PCT/EP2021/084133

(22) International Filing Date:

03 December 2021 (03.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20211862.6	04 December 2020 (04.12.2020)	EP
21158806.6	23 February 2021 (23.02.2021)	EP
21163696.4	19 March 2021 (19.03.2021)	EP
21172671.6	07 May 2021 (07.05.2021)	EP
21177336.1	02 June 2021 (02.06.2021)	EP
21205447.2	29 October 2021 (29.10.2021)	EP


(71) Applicants: **MORPHOSYS AG** [DE/DE]; Semmelweisstr. 7, 82152 Planegg (DE). **INCYTE CORPORATION**

(74) Agent: **SPILLER, Stephan** et al.; Morphosys AG, Semmelweisstr. 7, 82152 Planegg (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: ANTI-CD19 COMBINATION THERAPY

FIGURE 1: Trial design



(57) Abstract: The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and R-CHOP or an anti-CD19 antibody, lenalidomide, and R-CHOP for use in the treatment of diffuse large B cell lymphoma. The present disclosure is also directed to a therapeutic combination of an anti-CD19 antibody, lenalidomide, and rituximab for use in the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, or acute lymphoblastic leukemia.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(88) Date of publication of the international search report:

14 July 2022 (14.07.2022)